Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.
暂无分享,去创建一个
F Barkhof | F. Barkhof | C. Polman | M. V. van Walderveen | J. V. van Waesberghe | L. Truyen | B. V. van Oosten | J. Castelijns | G. J. Nijeholt | J H van Waesberghe | J A Castelijns | L. Truyen | M A van Walderveen | L Truyen | B W van Oosten | G J Lycklama à Nijeholt | C Polman | B. W. Oosten | J. V. Waesberghe | G. Lycklama à Nijeholt | M. V. Walderveen
[1] F. Barkhof,et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.
[2] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[3] A J Thompson,et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.
[4] R H Edwards,et al. Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the "invisible" lesion load. , 1994, Magnetic resonance imaging.
[5] J A Frank,et al. Serial contrast‐enhanced magnetic resonance imaging in patients with early relapsing–remitting multiple sclerosis: Implications for treatment trials , 1994, Annals of neurology.
[6] H. Lassmann,et al. Histopathology and the blood–cerebrospinal fluid barrier in multiple sclerosis , 1994, Annals of neurology.
[7] F. Barkhof,et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.
[8] P. Albert,et al. Blood‐brain barrier disruption on contrast‐enhanced MRI in patients with mild relapsing‐remitting multiple sclerosis , 1995, Neurology.
[9] A J Thompson,et al. Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis , 1996, Multiple sclerosis.
[10] F. Barkhof,et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial , 1997, Neurology.
[11] R E Lenkinski,et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis , 1994, Magnetic resonance in medicine.
[12] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[13] P. Scheltens,et al. MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. , 1997, AJNR. American journal of neuroradiology.
[14] F. Barkhof,et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. , 1992, AJR. American journal of roentgenology.
[15] F. Barkhof,et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.
[16] R I Grossman,et al. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: Estimation of macroscopic and microscopic disease burden , 1996, Magnetic resonance in medicine.
[17] H. Tobi,et al. Correlating MRI and clinical disease activity in multiple sclerosis , 1995, Neurology.
[18] A. Thompson,et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.
[19] F. Barkhof,et al. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials , 1997, Multiple Sclerosis.
[20] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[21] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[22] A. Thompson,et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[23] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[24] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[25] J. Taubenberger,et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.
[26] B E Kendall,et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.
[27] D. N. Landon,et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. , 1990, Brain : a journal of neurology.
[28] H. McFarland,et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.
[29] F. Barkhof,et al. Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis , 1998, Annals of neurology.
[30] Hans Lassmann,et al. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.
[31] F. Barkhof,et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.